Field Trip Health & Wellness Ltd. (FTHWF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Field Trip Health & Wellness Ltd. (FTHWF) Healthcare & Pipeline Overview

Field Trip Health & Wellness Ltd. is a biotechnology company focused on psychedelic therapies, operating health centers across North America and Europe. With a presence in a niche market, the company aims to provide innovative treatments for mental health, but faces challenges typical of early-stage biotech firms.

What Is the Investment Thesis for FTHWF?

Field Trip Health & Wellness Ltd. presents a speculative investment opportunity within the emerging psychedelic therapy market. The company's focus on developing and delivering psychedelic-assisted treatments for mental health conditions positions it to capitalize on the growing acceptance and legalization of these therapies. Key value drivers include the expansion of its health center network and the development of proprietary psychedelic molecules. However, the company faces significant risks, including regulatory hurdles, competition from other biotech firms, and the need for substantial capital investment. With a current P/E ratio of -0.34 and no dividend, the company's financial performance is closely tied to its ability to successfully navigate these challenges and achieve commercial success. The absence of a market cap suggests significant volatility and uncertainty. Investors should carefully consider these factors before investing.

Based on FMP financials and quantitative analysis

FTHWF Key Highlights

• Operates health centers providing psychedelic therapies in North America and Europe.
• Focuses on developing innovative treatments for mental health conditions.
• Based in Toronto, Canada, indicating a North American operational focus.
• P/E ratio of -0.34 reflects current losses and the early stage of the company.
• No dividend yield, typical for growth-focused biotechnology companies reinvesting earnings.

Who Are FTHWF's Competitors?

FTHWF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FTHWF's Key Strengths?

• First-mover advantage in the psychedelic therapy market.
• Established network of health centers.
• Focus on research and development of proprietary molecules.
• Experienced management team with expertise in biotechnology and healthcare.

What Are FTHWF's Weaknesses?

• Limited operating history and financial resources.
• Dependence on regulatory approvals for market expansion.
• High capital expenditure requirements for research and development.
• Negative P/E ratio indicates current losses.

What Could Drive FTHWF Stock Higher?

• Regulatory approvals for psychedelic therapies in key jurisdictions could expand market access.
• Expansion of the health center network to new locations in North America and Europe.
• Progress in clinical trials for proprietary psychedelic molecules.
• Strategic partnerships with pharmaceutical companies and research institutions.
• Increasing public awareness and acceptance of psychedelic treatments.

What Are the Key Risks for FTHWF?

• Financial-distress signal — its Altman Z-Score of -6.28 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles and evolving legal landscape could delay or prevent market expansion.
• Competition from other biotechnology companies in the psychedelic therapy market.
• Adverse side effects and safety concerns associated with psychedelic substances.
• Negative public perception and stigma associated with psychedelic treatments.
• Dependence on securing funding and achieving commercial success.

What Are the Growth Opportunities for FTHWF?

• Expansion of Health Center Network: Field Trip has the opportunity to expand its network of health centers across North America and Europe. Each new center increases the company's capacity to deliver psychedelic therapies and generate revenue. The market for mental health treatments is substantial, with an estimated value of $100 billion globally. Successful expansion depends on securing necessary regulatory approvals and managing operational costs effectively. The timeline for expansion is ongoing, with new centers planned for key metropolitan areas over the next 3-5 years.
• Development of Proprietary Psychedelic Molecules: Investing in research and development to create proprietary psychedelic molecules offers a significant growth opportunity. Patent protection on these molecules could provide a competitive advantage and generate substantial revenue streams. The market for novel therapeutics is highly lucrative, with successful drugs often achieving blockbuster status. This development is an ongoing process, with initial clinical trials expected to begin within the next 2 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies, research institutions, and other healthcare providers can accelerate the development and commercialization of psychedelic therapies. These partnerships can provide access to funding, expertise, and distribution channels. The market for collaborative drug development is robust, with numerous examples of successful partnerships in the biotechnology industry. The timeline for establishing these partnerships is immediate, with ongoing discussions with potential collaborators.
• Increased Public Awareness and Acceptance: As public awareness and acceptance of psychedelic therapies increase, the demand for Field Trip's services is likely to grow. Educating the public about the potential benefits of these therapies can help to reduce stigma and encourage more people to seek treatment. The market for mental health education and awareness is expanding, with various organizations working to promote mental wellness. This is an ongoing effort, with continuous outreach and engagement activities planned.
• Regulatory Approvals and Legalization: Obtaining regulatory approvals for psychedelic therapies in various jurisdictions is crucial for long-term growth. As more countries and states legalize or decriminalize these substances, the market for Field Trip's services will expand. The regulatory landscape is evolving, with ongoing discussions and legislative initiatives in several regions. The timeline for achieving these approvals varies, but significant progress is expected over the next 5-10 years.

What Opportunities Does FTHWF Have?

• Expanding health center network across North America and Europe.
• Securing regulatory approvals for psychedelic therapies in various jurisdictions.
• Forming strategic partnerships with pharmaceutical companies and research institutions.
• Increasing public awareness and acceptance of psychedelic treatments.

What Threats Does FTHWF Face?

• Regulatory hurdles and evolving legal landscape.
• Competition from other biotechnology companies in the psychedelic therapy market.
• Potential for adverse side effects and safety concerns.
• Negative public perception and stigma associated with psychedelic substances.

What Are FTHWF's Competitive Advantages?

• First-mover advantage in the emerging psychedelic therapy market.
• Proprietary treatment protocols and therapeutic approaches.
• Established network of health centers providing specialized care.
• Investment in research and development to create proprietary psychedelic molecules.

What Does FTHWF Do?

Field Trip Health & Wellness Ltd., based in Toronto, Canada, is dedicated to the development and delivery of psychedelic therapies. The company operates health centers in North America and Europe, providing treatments for mental health conditions. Founded with the vision of transforming mental healthcare through psychedelic-assisted therapy, Field Trip aims to address conditions such as depression, anxiety, and PTSD. The company's approach involves combining psychedelic substances, such as psilocybin and ketamine, with psychotherapy to enhance treatment outcomes. Field Trip's health centers offer a controlled and supportive environment for these therapies, ensuring patient safety and comfort. The company also invests in research and development to explore new psychedelic compounds and treatment protocols. Field Trip's strategy includes expanding its network of health centers and developing proprietary psychedelic molecules. The company seeks to establish itself as a leader in the emerging field of psychedelic medicine, providing innovative and effective treatments for mental health disorders. As of 2026, Field Trip continues to navigate the regulatory landscape and build its clinical infrastructure to support the growing demand for psychedelic therapies.

What Products and Services Does FTHWF Offer?

• Operates health centers that provide psychedelic therapies.
• Offers treatments for mental health conditions such as depression, anxiety, and PTSD.
• Combines psychedelic substances with psychotherapy to enhance treatment outcomes.
• Provides a controlled and supportive environment for psychedelic therapies.
• Invests in research and development to explore new psychedelic compounds.
• Expands its network of health centers across North America and Europe.
• Develops proprietary psychedelic molecules for therapeutic use.

How Does FTHWF Make Money?

• Generates revenue by providing psychedelic-assisted therapy services at its health centers.
• Invests in research and development to create proprietary psychedelic molecules.
• Seeks strategic partnerships and collaborations to expand its reach and capabilities.

What Industry Does FTHWF Operate In?

Field Trip Health & Wellness Ltd. operates within the rapidly evolving biotechnology industry, specifically targeting the emerging market for psychedelic therapies. This market is characterized by increasing interest in alternative mental health treatments and growing acceptance of psychedelic substances for therapeutic use. The competitive landscape includes companies like AWKNF (Awakn Life Sciences Corp.), BRRGF (Braxia Scientific Corp.), DOGP (atai Life Sciences N.V.), HERTF (Cybin Inc.), and IPCIF (Revive Therapeutics Ltd.), all exploring various approaches to psychedelic medicine. The industry faces regulatory hurdles and requires significant investment in research and clinical trials. Market trends indicate a growing demand for innovative mental health solutions, positioning Field Trip to potentially benefit from this trend.

Who Are FTHWF's Key Customers?

• Individuals suffering from mental health conditions such as depression, anxiety, and PTSD.
• Patients seeking alternative treatments for mental health disorders.
• Healthcare providers and institutions interested in offering psychedelic therapies.

FTHWF Valuation & Market Position

With a $3.71M market cap, Field Trip Health & Wellness Ltd. sits in the micro-cap segment of the market. Relative to its peer group, FTHWF's quantitative score of 38/100 is below the peer average of 74/100.

F-Score 3/9Financial Health

Field Trip Health & Wellness Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.28 places it in the distress zone, a signal of elevated financial risk.

FTHWF Financials

FTHWF Latest News

No recent news available for FTHWF.

FTHWF Analyst Consensus

FTHWF MoonshotScore

What Investors Ask About Field Trip Health & Wellness Ltd. (FTHWF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources